Servier Completes Acquisition of Day One Biopharmaceuticals; Shares Delisted
Summary
Servier has successfully completed its tender offer to acquire Day One Biopharmaceuticals for $21.50 per share, resulting in the company becoming a wholly-owned subsidiary and its shares being delisted from Nasdaq.
Key Events
-
Tender Offer Completed
Servier successfully completed its tender offer for all outstanding shares of Day One Biopharmaceuticals, with approximately 85.34% of shares validly tendered.
-
Acquisition Finalized
On April 23, 2026, Servier completed the acquisition of Day One Biopharmaceuticals, which is now a wholly-owned subsidiary of Servier Pharmaceuticals LLC.
-
Shares Delisted
Day One's common stock ceased trading on Nasdaq prior to the commencement of trading on April 23, 2026, and the company has requested delisting and deregistration.
-
Transaction Value
The acquisition represents a total equity value of approximately $2.5 billion, with shareholders receiving $21.50 per share.
Analysis
This filing officially confirms the successful completion of Servier's tender offer to acquire Day One Biopharmaceuticals. The acquisition, valued at approximately $2.5 billion, marks the definitive end of Day One Biopharmaceuticals as an independent public entity. Shareholders who validly tendered their shares received $21.50 per share, which is at the company's 52-week high, representing a favorable exit. The company's common stock has ceased trading on Nasdaq and will be delisted, removing it from public markets. This event fundamentally alters the investment thesis for Day One Biopharmaceuticals, as it is no longer a publicly tradable company.
At the time of this filing, DAWN was trading at $21.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $5.64 to $21.53. This filing was assessed with positive market sentiment and an importance score of 10 out of 10.